ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
Active, not recruiting · NCT07011706 · Registry updated 2026-09-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Active, not recruiting | Phase 2 | 2026-09-29 | NCT07011706 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Aclaris Therapeutics, Inc. | 3 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Aclaris Site | Mississauga | Canada | 1 |
| Aclaris Site | Toronto | Canada | 1 |
| Aclaris Site | Richmond Hill | Canada | 1 |
| Aclaris Site | Markham | Canada | 1 |